We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Sensitive Analyzer Detects Blood Biomarker for Traumatic Brain Injury

By LabMedica International staff writers
Posted on 18 Aug 2015
Traumatic brain injury (TBI) is recognized as the signature injury in military personnel deployed for combat operations, and combat injuries and injuries in non-deployed settings have resulted in more than 300,000 TBI cases, with many experiencing multiple TBIs.

Tau is a microtubule-associated protein that functions as a structural element in the axonal cytoskeleton and elevations of tau concentration are an indication of axonal injury and are observed in the cerebral spinal fluid and peripheral blood of patients with severe TBI, professional boxers, and concussed athletes.

Scientists at the National Institute of Nursing Research, (NINR; Bethesda, MD, USA) and their colleagues carried out an observational assessment from September 2012 to August 2014 on 70 military patients with self-reported TBI and compared their tau concentrations in blood plasma to a control group consisting of 28 subjects. More...
Non-fasting blood samples were collected into plastic dipotassium EDTA tubes, placed on ice, and centrifuged at 2,000 × g for 15 minutes at 4 °C, and plasma was aliquoted.

Tau concentrations in plasma samples were measured with a digital array technology (Quanterix Corporation; Lexington, MA, USA), which uses a single-molecule enzyme-linked immunoarray (Simoa) method. The Simoa Human Total Tau assay uses a combination of a monoclonal capture antibody that reacts with a linear epitope in the mid-region of all tau isoforms, and a detection antibody that reacts with a linear epitope in the N-terminus of total tau. The limit of detection for this assay is 0.012 pg/mL.

A significantly elevated concentration of total tau with a mean of 1.13 ± 0.78 pg/mL was found in the self-reported TBI group compared with the control group whose mean was 0.63 ± 0.48 pg/mL. Within the self-reported TBI cases, plasma total tau concentrations were significantly associated with having a medical record of TBI compared with self-reported TBI only. The severity of total post concussive symptoms correlated with total tau concentrations in the self-reported TBI group. They also found that participants with three or more deployment-related TBIs had significantly higher levels of tau compared with participants who had fewer TBIs.

The authors concluded that increases in total tau concentration in the peripheral blood in military personnel with multiple TBIs and chronic post concussive disorder (PCD) symptoms suggest that tau accumulations may contribute to chronic neurological symptoms following TBI. E. Kevin Hrusovsky, PhD, CEO of Quanterix Corporation, said, “This is one of the many studies in which Simoa is being used to further understand and quantify the long term effects of TBI and we are pleased to be working with NINR to continue our mission to understand what is going on in the human body and, in turn, improve the quality of care.” The study was published on August 3, 2015, in the journal JAMA Neurology.

Related Links:

National Institute of Nursing Research  
Quanterix Corporation 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.